ORAMED PHARMACEUTICALS INC.

Oramed Pharmaceuticals Inc. reported a significant net income of $38.31 million for the three months ended March 31, 2026, a substantial improvement from a net loss of $7.64 million in the prior year. This was largely driven by a $5.82 million gain from the sale of its POD technology platform to Lifeward Ltd. and $2.00 million income from the Medicox License Agreement. The company also made a strategic investment in Lifeward, receiving equity, warrants, and senior secured convertible notes, and paid $10.36 million in dividends.